Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paritaprevir + ritonavir
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paritaprevir + ritonavir is a fixed-dose combination of two small molecule drugs used as part of direct-acting antiviral regimens for the treatment of chronic hepatitis C virus (HCV) infection. Paritaprevir (code name: ABT-450) is a potent inhibitor of the HCV NS3/4A protease, which is essential for viral replication. Ritonavir acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A4 (CYP3A4), thereby increasing plasma concentrations and prolonging the half-life of paritaprevir to allow once-daily dosing. This combination has been studied and used in conjunction with other antivirals such as ombitasvir (ABT-267) and dasabuvir (ABT-333), forming an all-oral regimen that enables interferon-free treatment for HCV genotype 1 infection[4][5][8]. The regimen was developed primarily by AbbVie.
- Brand names
- TechnivieViekira PakHolkira Pak
- Other names
- paritaprevir + ritonavirABT-450/ritonavirABT-450/r
02
Targets
CYP3A4 (Cytochrome P450 3A4)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on paritaprevir + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paritaprevir + ritonavir.